Evidence map›Paper›PMID 36755247›Full record

ArticleBMC gastroenterology2023

The expression of SERPINE1 in colon cancer and its regulatory network and prognostic value.

Yigang Wang, Jinyan Wang, Jianchao Gao, Mei Ding, Hua Li

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Prognostic Significance ofBiomedicines · 2025
    Article
  11. Deciphering the Expression, Functional Role, and Prognostic Significance ofJournal of obstetrics and gynaecology of India · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. World journal of gastrointestinal oncology · 2024
    Article
  17. Characterization of TFIIE-regulated genes by transcriptome analysis.Turkish journal of biology = Turk biyoloji dergisi · 2024
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yigang Wang *Anus and Intestine Surgery, Tangshan Central Hospital, Tangshan, 063000, Hebei, China.
Jinyan Wang *Anus and Intestine Surgery, Tangshan Central Hospital, Tangshan, 063000, Hebei, China.
Jianchao GaoAnus and Intestine Surgery, Tangshan Central Hospital, Tangshan, 063000, Hebei, China.
Mei DingAnus and Intestine Surgery, Tangshan Central Hospital, Tangshan, 063000, Hebei, China.
Hua LiDepartment of Gastrointestinal Surgery, Tangshan Central Hospital, Tangshan Youyi Road and Changning Road Interchange Westbound 300 Meters, Tangshan, 063000, China. L1huaaaaaaaaa@163.com.
Tangshan People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerpin Peptidase Inhibitor 1 (SERPINE1) promotes cancer progression by making it easier for cancer cells to spread to surrounding normal tissue. We expect to understand the prognostic value and regulatory network of SERPINE1 in colon cancer using bioinformatics methods.

methodsThe expression of target gene SERPINE1 in varying cancers was analyzed by the Tumor Immune Estimation Resource (TIMER) database. SERPINE1 expression in Colon Adenocarcinoma and normal tissue samples was assessed by starBase and UALCAN databases. SERPINE1 expression in clinical tissues was assayed using quantitative reverse transcription Polymerase Chain Reaction (qRT-PCR). SERPINE1 expression was detected in colon cancer patients with various clinical features (age, gender, nodal metastasis status, race, stages, and subtype) using analysis of variance. Survival curve was used to analyze the effect of high and low expression of SERPINE1 on the survival time of patients with different clinical phenotypes. Gene Set Enrichment Analysis (GSEA) was conducted on the results of LinkFinder calculation using LinkInterpreter module, which was combined with Pearson correlation analysis to obtain the kinase targets and miRNA targets, transcription factor targets, and corresponding signaling pathways associated with SERPINE1. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed on GSEA result. Finally, Gene Multiple Association Network Integration Algorithm (GeneMANIA) was utilized to establish a network of genes related to the kinases MAPK1, miR-18a, and SRF_Q, and biological functions were analyzed.

resultsBased on TIMER, starBase, and UALCAN databases, SERPINE1 was found to be remarkably highly expressed in colon cancer patients, which was further verified by clinical tissue. It was also associated with different clinical features (nodal metastasis status, stages, subtypes). Additionally, survival analysis showed that patients with low expression of SERPINE1 had a longer survival time, suggesting that SERPINE1 was a prognostic risk factor for colon cancer. Pearson correlation analysis revealed that the expression of Integrin Alpha 5 (ITGA5), Matrix Metallopeptidase 19 (MMP19), and ADAM Metallopeptidase with Thrombospondin Type 1 Motif, 4 (ADAMTS4) had the highest correlation with that of SERPINE1. The GSEA results indicated that these genes were mainly enriched in the pathways of RNA expression and kinases. Finally, GeneMANIA analysis was introduced to construct the molecular network of SERPINE1.

conclusionOverall, our bioinformatics analyses comprehensively described the networks involved SERPINE1 in colon cancer and the potentially associated molecular mechanisms.

Indexed as

AdenocarcinomaColonic NeoplasmsSerpinsHumansPeptide HydrolasesPlasminogen Activator Inhibitor 1PrognosisPeptide HydrolasesPlasminogen Activator Inhibitor 1SERPINE1 protein, humanSerpinsBioinformaticsColon cancerLinkedOmicsRegulatory networkSERPINE1UALCAN

Identifiers

PMID36755247
PMCPMC9906885
OpenAlexW4319599114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.